(Q38321330)

2 September 2017

1 reference

title

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases (English)

1 reference

2 September 2017

0 references

Ebola hemorrhagic fever

0 references

Orthoebolavirus zairense

0 references

1 reference

3

Sarah C Gilbert

0 references

Teresa Lambe

object named as

Teresa Lambe

series ordinal

2

0 references

Adrian V. S. Hill

series ordinal

4

object named as

Adrian V S Hill

1 reference

2 September 2017

1

Claire M Tully

1 reference

2 September 2017

language of work or name

1 reference

14 January 2015

1 reference

Lancet Infectious Diseases

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

356-359

1 reference

Emergence of Zaire Ebola Virus Disease in Guinea

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

US signs contract with ZMapp maker to accelerate development of the Ebola drug

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Clinical care of two patients with Ebola virus disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

1 reference

7 January 2021

Liberian man being treated for Ebola in Texas dies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Hark back: passive immunotherapy for influenza and other serious infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Successful topical respiratory tract immunization of primates against Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Ebola haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971071-0

7 January 2021

10.1016/S1473-3099(14)71071-0

Identifiers

DOI

1 reference

2 September 2017

1 reference